Identification of Chemoattractive Factors Involved in the Migration of Bone Marrow-derived Mesenchymal Stem Cells to Brain Lesions Caused by Prions

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2011 Aug 5

PMID 21813601

Citations 18

Authors

Chang-Hyun Song

Osamu Honmou

Hidefumi Furuoka

Motohiro Horiuchi

Affiliations

Soon will be listed here.

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) have been reported to migrate to brain lesions of neurodegenerative diseases; however, the precise mechanisms by which MSCs migrate remain to be elucidated. In this study, we carried out an in vitro migration assay to investigate the chemoattractive factors for MSCs in the brains of prion-infected mice. The migration of immortalized human MSCs (hMSCs) was reduced by their pretreatment with antibodies against the chemokine receptors, CCR3, CCR5, CXCR3, and CXCR4 and by pretreatment of brain extracts of prion-infected mice with antibodies against the corresponding ligands, suggesting the involvement of these receptors, and their ligands in the migration of hMSCs. In agreement with the results of an in vitro migration assay, hMSCs in the corpus callosum, which are considered to be migrating from the transplanted area toward brain lesions of prion-infected mice, expressed CCR3, CCR5, CXCR3, and CXCR4. The combined in vitro and in vivo analyses suggest that CCR3, CCR5, CXCR3, and CXCR4, and their corresponding ligands are involved in the migration of hMSCs to the brain lesions caused by prion propagation. In addition, hMSCs that had migrated to the right hippocampus of prion-infected mice expressed CCR1, CX3CR1, and CXCR4, implying the involvement of these chemokine receptors in hMSC functions after chemotactic migration. Further elucidation of the mechanisms that underlie the migration of MSCs may provide useful information regarding application of MSCs to the treatment of prion diseases.

Citing Articles

CCL2/CCR2 Signalling in Mesenchymal Stem/Progenitor Cell Recruitment and Fracture Healing in Mice.

Kannan R, Koh A, Kent 3rd R, Bhutada K, Wasi F, Wagner L J Cell Mol Med. 2024; 28(24):e70300.

PMID: 39721002 PMC: 11669326. DOI: 10.1111/jcmm.70300.

The Role of CXCR3 in Nervous System-Related Diseases.

Wang F, Guo B, Jia Z, Jing Z, Wang Q, Li M Mediators Inflamm. 2024; 2024:8347647.

PMID: 39429695 PMC: 11488998. DOI: 10.1155/2024/8347647.

Regenerative potential of mesenchymal stromal cells in wound healing: unveiling the influence of normoxic and hypoxic environments.

Mahjoor M, Fakouri A, Farokhi S, Nazari H, Afkhami H, Heidari F Front Cell Dev Biol. 2023; 11:1245872.

PMID: 37900276 PMC: 10603205. DOI: 10.3389/fcell.2023.1245872.

Potential Therapeutic Use of Stem Cells for Prion Diseases.

Zayed M, Kook S, Jeong B Cells. 2023; 12(19).

PMID: 37830627 PMC: 10571911. DOI: 10.3390/cells12192413.

Aged mesenchymal stem cells and inflammation: from pathology to potential therapeutic strategies.

Yang X, Wang Y, Rovella V, Candi E, Jia W, Bernassola F Biol Direct. 2023; 18(1):40.

PMID: 37464416 PMC: 10353240. DOI: 10.1186/s13062-023-00394-6.

References

Azizi S, Stokes D, Augelli B, DiGirolamo C, Prockop D . Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats--similarities to astrocyte grafts. Proc Natl Acad Sci U S A. 1998; 95(7):3908-13. PMC: 19936. DOI: 10.1073/pnas.95.7.3908. View

Riemer C, Schultz J, Burwinkel M, Schwarz A, Mok S, Gultner S . Accelerated prion replication in, but prolonged survival times of, prion-infected CXCR3-/- mice. J Virol. 2008; 82(24):12464-71. PMC: 2593330. DOI: 10.1128/JVI.01371-08. View

Prockop D . Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276(5309):71-4. DOI: 10.1126/science.276.5309.71. View

Ponte A, Marais E, Gallay N, Langonne A, Delorme B, Herault O . The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2007; 25(7):1737-45. DOI: 10.1634/stemcells.2007-0054. View

Chopp M, Li Y . Treatment of neural injury with marrow stromal cells. Lancet Neurol. 2003; 1(2):92-100. DOI: 10.1016/s1474-4422(02)00040-6. View

Lee P, Kim J, Bang O, Ahn Y, Joo I, Huh K . Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther. 2007; 83(5):723-30. DOI: 10.1038/sj.clpt.6100386. View

Xiang W, Windl O, Wunsch G, Dugas M, Kohlmann A, Dierkes N . Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J Virol. 2004; 78(20):11051-60. PMC: 521804. DOI: 10.1128/JVI.78.20.11051-11060.2004. View

Kopen G, Prockop D, Phinney D . Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A. 1999; 96(19):10711-6. PMC: 17948. DOI: 10.1073/pnas.96.19.10711. View

Trevitt C, Collinge J . A systematic review of prion therapeutics in experimental models. Brain. 2006; 129(Pt 9):2241-65. DOI: 10.1093/brain/awl150. View

10.

Haynes S, Hollopeter G, Yang G, Kurpius D, Dailey M, Gan W . The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006; 9(12):1512-9. DOI: 10.1038/nn1805. View

11.

Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M . Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett. 2001; 316(2):67-70. DOI: 10.1016/s0304-3940(01)02384-9. View

12.

Hofstetter C, Schwarz E, Hess D, Widenfalk J, El Manira A, Prockop D . Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci U S A. 2002; 99(4):2199-204. PMC: 122342. DOI: 10.1073/pnas.042678299. View

13.

Uryu M, Karino A, Kamihara Y, Horiuchi M . Characterization of prion susceptibility in Neuro2a mouse neuroblastoma cell subclones. Microbiol Immunol. 2007; 51(7):661-9. DOI: 10.1111/j.1348-0421.2007.tb03954.x. View

14.

Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F . Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008; 15(10):730-8. DOI: 10.1038/gt.2008.39. View

15.

Campbell I, Eddleston M, Kemper P, Oldstone M, Hobbs M . Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie. J Virol. 1994; 68(4):2383-7. PMC: 236715. DOI: 10.1128/JVI.68.4.2383-2387.1994. View

16.

Fox J, Chamberlain G, Ashton B, Middleton J . Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol. 2007; 137(6):491-502. DOI: 10.1111/j.1365-2141.2007.06610.x. View

17.

Son B, Marquez-Curtis L, Kucia M, Wysoczynski M, Turner A, Ratajczak J . Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 2006; 24(5):1254-64. DOI: 10.1634/stemcells.2005-0271. View

18.

Rappert A, Bechmann I, Pivneva T, Mahlo J, Biber K, Nolte C . CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci. 2004; 24(39):8500-9. PMC: 6729901. DOI: 10.1523/JNEUROSCI.2451-04.2004. View

19.

Huang D, Shi F, Jung S, Pien G, Wang J, Salazar-Mather T . The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006; 20(7):896-905. DOI: 10.1096/fj.05-5465com. View

20.

Wang L, Li Y, Chen J, Gautam S, Zhang Z, Lu M . Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp Hematol. 2002; 30(7):831-6. DOI: 10.1016/s0301-472x(02)00829-9. View